Published in EMBO J on September 01, 2014
The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer. Clin Cancer Res (2015) 0.97
The Hippo/YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression. EMBO Mol Med (2015) 0.90
A Review: Molecular Aberrations within Hippo Signaling in Bone and Soft-Tissue Sarcomas. Front Oncol (2015) 0.88
ERK and p38 MAPK Activities Determine Sensitivity to PI3K/mTOR Inhibition via Regulation of MYC and YAP. Cancer Res (2016) 0.81
Deubiquitylating enzyme USP9x regulates hippo pathway activity by controlling angiomotin protein turnover. Cell Discov (2016) 0.81
YAP1 and TAZ Control Pancreatic Cancer Initiation in Mice by Direct Up-regulation of JAK-STAT3 Signaling. Gastroenterology (2016) 0.81
Deciphering KRAS and NRAS mutated clone dynamics in MLL-AF4 paediatric leukaemia by ultra deep sequencing analysis. Sci Rep (2016) 0.80
Differential growth triggers mechanical feedback that elevates Hippo signaling. Proc Natl Acad Sci U S A (2016) 0.79
Targeting KRas-dependent tumour growth, circulating tumour cells and metastasis in vivo by clinically significant miR-193a-3p. Oncogene (2016) 0.79
Independent and core pathways in oncogenic KRAS signaling. Expert Rev Proteomics (2016) 0.78
Angiomotin stabilization by tankyrase inhibitors antagonizes constitutive TEAD-dependent transcription and proliferation of human tumor cells with Hippo pathway core component mutations. Oncotarget (2016) 0.77
Multiparametric Analysis of Cell Shape Demonstrates that β-PIX Directly Couples YAP Activation to Extracellular Matrix Adhesion. Cell Syst (2017) 0.77
Cell density regulates cancer metastasis via the Hippo pathway. Future Oncol (2015) 0.77
The RAS and YAP1 dance, who is leading? EMBO J (2014) 0.77
YAP modulates TGF-β1-induced simultaneous apoptosis and EMT through upregulation of the EGF receptor. Sci Rep (2017) 0.75
A novel brain tumour model in zebrafish reveals the role of YAP activation in MAPK/PI3K induced malignant growth. Dis Model Mech (2016) 0.75
DUB3 Deubiquitylating Enzymes Regulate Hippo Pathway Activity by Regulating the Stability of ITCH, LATS and AMOT Proteins. PLoS One (2017) 0.75
The MST/Hippo Pathway and Cell Death: A Non-Canonical Affair. Genes (Basel) (2016) 0.75
A cell-autonomous tumour suppressor role of RAF1 in hepatocarcinogenesis. Nat Commun (2016) 0.75
Crystal structure of TAZ-TEAD complex reveals a distinct interaction mode from that of YAP-TEAD complex. Sci Rep (2017) 0.75
USP21 regulates Hippo pathway activity by mediating MARK protein turnover. Oncotarget (2017) 0.75
Targeting YAP/TAZ-TEAD protein-protein interactions using fragment-based and computational modeling approaches. PLoS One (2017) 0.75
Comprehensive molecular characterization of human colon and rectal cancer. Nature (2012) 34.13
Creation of human tumour cells with defined genetic elements. Nature (1999) 16.47
Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev (2007) 13.05
Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell (2007) 13.04
Role of YAP/TAZ in mechanotransduction. Nature (2011) 11.56
Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev (2001) 11.25
A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell (2006) 11.01
The hippo signaling pathway in development and cancer. Dev Cell (2010) 10.54
TEAD mediates YAP-dependent gene induction and growth control. Genes Dev (2008) 9.88
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature (2012) 9.39
Identification of a chromosome 18q gene that is altered in colorectal cancers. Science (1990) 8.32
Tumor suppressor LATS1 is a negative regulator of oncogene YAP. J Biol Chem (2007) 5.49
A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). Genes Dev (2010) 5.38
The Hippo pathway and human cancer. Nat Rev Cancer (2013) 5.17
Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature (2001) 5.07
TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol Cell Biol (2008) 5.02
Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol Cell Biol (2002) 4.77
Hippo pathway inhibits Wnt signaling to restrain cardiomyocyte proliferation and heart size. Science (2011) 4.76
Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature (2004) 4.35
Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev (2012) 4.19
Archipelago regulates Cyclin E levels in Drosophila and is mutated in human cancer cell lines. Nature (2001) 3.50
Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases. Oncogene (2004) 3.27
YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway. Nat Cell Biol (2009) 3.26
KRAS and YAP1 converge to regulate EMT and tumor survival. Cell (2014) 3.06
The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat Rev Drug Discov (2013) 3.03
The Hippo signaling pathway restricts the oncogenic potential of an intestinal regeneration program. Genes Dev (2010) 3.02
Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer. Cancer Cell (2013) 2.64
Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell (2014) 2.50
The tumor-suppressive functions of the human INK4A locus. Cancer Cell (2003) 2.31
The hippo tumor pathway promotes TAZ degradation by phosphorylating a phosphodegron and recruiting the SCF{beta}-TrCP E3 ligase. J Biol Chem (2010) 2.27
Spatial organization of Hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin/NF2. Cell (2013) 2.16
Expression of human cytokines dramatically improves reconstitution of specific human-blood lineage cells in humanized mice. Proc Natl Acad Sci U S A (2009) 1.99
Overexpression of YAP and TAZ is an independent predictor of prognosis in colorectal cancer and related to the proliferation and metastasis of colon cancer cells. PLoS One (2013) 1.81
Regulation of Hippo signaling by EGFR-MAPK signaling through Ajuba family proteins. Dev Cell (2013) 1.78
The Hippo superhighway: signaling crossroads converging on the Hippo/Yap pathway in stem cells and development. Curr Opin Cell Biol (2013) 1.64
Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling. Cancer Discov (2012) 1.62
TAZ expression as a prognostic indicator in colorectal cancer. PLoS One (2013) 1.55
Roles of F-box proteins in cancer. Nat Rev Cancer (2014) 1.51
Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas. Genes Chromosomes Cancer (2010) 1.50
Loss of FBXW7, a cell cycle regulating gene, in colorectal cancer: clinical significance. Int J Cancer (2010) 1.49
Mutant K-Ras activation of the proapoptotic MST2 pathway is antagonized by wild-type K-Ras. Mol Cell (2011) 1.44
Immunopurification of Ago1 miRNPs selects for a distinct class of microRNA targets. Proc Natl Acad Sci U S A (2009) 1.26
Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer. Br J Cancer (2010) 1.11
The SOCS box-adapting proteins for ubiquitination and proteasomal degradation. IUBMB Life (2012) 1.02
Oncogenic cooperation between SOCS family proteins and EGFR identified using a Drosophila epithelial transformation model. Genes Dev (2012) 0.97
An update on targeting Hippo-YAP signaling in liver cancer. Expert Opin Ther Targets (2012) 0.95
Ubiquitylation in immune disorders and cancer: from molecular mechanisms to therapeutic implications. EMBO Mol Med (2012) 0.94
Expression of SOCSs in human prostate cancer and their association in prognosis. Mol Cell Biochem (2013) 0.87
Reduced expression of SOCS2 and SOCS6 in hepatocellular carcinoma correlates with aggressive tumor progression and poor prognosis. Mol Cell Biochem (2013) 0.81